Mibefradil clinical trials
Also written Posicor.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses Mibefradil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Cavion, Inc. (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Calcium channel blockers source
Studies
Open first, then newest update. How each study uses Mibefradil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBMCompletedPhase 1Cavion, Inc.NCT02202993Written as Mibefradil with Radiation
- Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent GliomaCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01480050Written as Mibefradil
- Safety Study of Mibefradil When Given Four Times a Day in Healthy VolunteersCompletedPhase 1Cavion, Inc.NCT01550458Written as mibefradil
Codes
What other systems call Mibefradil · ClinicalTrials.gg INT008768
- MeSH (NLM) D020748MibefradilConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 27B90X776AMIBEFRADILConfirmed FDA, NLM, Wikidata
- RxNorm 83213Confirmed FDA, Wikidata
- Wikidata Q6827783mibefradilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87686MibefradilOne source FDA
- DrugBank DB01388One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D020748 | Mibefradil | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 27B90X776A | MIBEFRADIL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 83213 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6827783 | mibefradil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87686 | Mibefradil | One source FDA |
| DrugBank | DB01388 | — | One source Wikidata |
Also registered as mibefradil dihydrochloride (UNII 842TUP3PQ8 · RxNorm 83214).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.